Vireo Health International (CSE: VREO) (OTC: VREOF) - Investor Dashboard
|Sector:||Health & Wellness|
|CEO:||Kyle Kingsley, M.D.|
|Fiscal Year-End:||Dec 31|
|Auditor:||Davidson & Company LLP|
|State with Operations:||10|
|Cash on hand:||$40.4 million|
|Fixed Investment:||$28.5 million|
|Shareholders’ Equity:||$109.3 million|
|Revenues – Last Quarter:||$5.8 million|
|Adj. Gross Margin :||36.6%|
Capital Structure (5/30/19)
|Last Financing:||12.1 million shares at US$4.25|
|As-converted Shares:||83.0 million|
|Diluted Shares:||107.8 million|
Vireo Health International, Inc. (CSE: VREO) (OTC: VREOF) is an American leading science-focused, multi-state cannabis company. Upon the successful completion of five pending acquisitions, the Company will operate in 11 states — Minnesota, New York, Pennsylvania, Maryland, Ohio, Rhode Island, Arizona, Massachusetts, Nevada, New Mexico and Puerto Rico.
Vireo’s physician-led team of more than 300 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries.
Using Science to Enable Cannabis Substitution for Opioids, Tobacco and Alcohol.
- Vireo has a 10-state footprint, with early operations in Minnesota, where it is one of two providers, and New York, where it was one of the first five operators
- Recently completed MA, NM, NV, and AZ acquisitions
- Vireo’s retail outlets are being transformed and rebranded to “Green Goods” dispensaries
- To date, successfully raised $113 million in debt and equity financing to support its multi-state operations and growth plans
- Vireo intends to continue to expand its footprint into multiple new states through cost-effective and opportunistic strategies which involve participating in competitive application processes and acquiring existing licensees
- The company has an LOI for an acquisition in California
- Entered the industrial hemp market and holds two hemp licenses through its wholly-owned subsidiaries
- Its extensive intellectual property portfolio has been developed to build a durable long-term business model that differs from peers
- Focused on transformative intellectual property ranging from novel product formulations, to agricultural scale cannabinoid production processes and equipment
- Vireo plans to leverage its medical, scientific and operational expertise to efficiently expand its operation in existing markets and enter new markets
- The company is focused on prudent capital allocation and aims to enter new markets cost effectively
Curated Stories & News
New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Vireo Health International, Inc. is a client of NCV Media, LLC. Read our full disclaimer.